^
BIOMARKER:

MAP2K1 mutation

i
Other names: MAP2K1, MAPKK1, MEK1, PRKMK1, Mitogen-activated protein kinase kinase 1
Entrez ID:
Related biomarkers:
MAP2K1 mutation
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
SITC 2021 - 2 weeks
MAP2K1 mutation
NSCLC
lorlatinib
Resistant: C3 – Early Trials
MAP2K1 mutation
Melanoma
CTLA4 inhibitor
Sensitive: C3 – Early Trials
MAP2K1 mutation
Biliary Tract Cancer
trametinib
Sensitive: C3 – Early Trials
MAP2K1 mutation
Lung Non-Squamous Non-Small Cell Cancer
binimetinib
Sensitive: C3 – Early Trials
MAP2K1 mutation
Ovarian Cancer
selumetinib
Sensitive: C4 – Case Studies
MAP2K1 mutation
Melanoma
dabrafenib
Resistant: D – Preclinical
MAP2K1 mutation
Melanoma
trametinib
Resistant: D – Preclinical